Determination of a novel phosphodiesterase4 inhibitor, 3‐[1‐(3cyclopropylmethoxy‐4‐difluoromethoxybenzyl)‐1H‐pyrazol‐3‐yl]‐benzoic acid (PDE‐423) in rat plasma using liquid chromatography–tandem mass spectrometry |
| |
| Authors: | Woon‐Ki Cho Hyewon Seo Sung Heum Choi Hyun Jeong Kwak Hyae Gyeong Cheon Dong Ju Jeon Sang Kyum Kim Myung Ae Bae Jin Sook Song |
| |
| Institution: | 1. Drug Discovery Platform Technology Group, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea;2. College of Pharmacy, ChungNam National University, Daejeon, Republic of Korea;3. Department of Pharmacology and Pharmaceutical Sciences, Gachon University of Medicine and Science, Incheon, Republic of Korea;4. Medicinal Chemistry Research Center, Division of Bio‐organic Science, Korea Research Institute of Chemical Technology, Republic of Korea |
| |
| Abstract: | A method for determining a novel phosphodiesterase‐4 inhibitor, 3‐1‐(3cyclopropylmethoxy‐4‐difluoromethoxybenzyl)‐1H‐pyrazol‐3‐yl]‐benzoic acid (PDE‐423), in rat plasma was developed and validated using liquid chromatography–tandem mass spectrometry for further pharmacokinetic study for development as a novel anti‐asthmatic drug. PDE‐423 in the concentration range of 0.02–10 µg/mL was linear with a correlation coefficient of >0.99, and the mean intra‐ and inter‐assay precisions of the assay were 7.50 and 3.86%, respectively. The validated method was used successfully for a pharmacokinetic study of PDE‐423 in rats. Copyright © 2014 John Wiley & Sons, Ltd. |
| |
| Keywords: | PDE‐423 method validation pharmacokinetics LC‐MS/MS rat plasma |
|
|
